Promising cancer drug trial pulled before it even started
NCT ID NCT06730100
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was a planned Phase 2 trial to test the drug CBX-12 in people with advanced colorectal cancer that had stopped responding to standard treatments. The drug was designed to deliver a cancer-killing substance directly to tumor cells. However, the study was withdrawn before any patients were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CBX-12 (a drug that links a peptide to an anticancer substance called exatecan)
- What this could lead to
- If it worked, CBX-12 could offer a new treatment option for patients with advanced colorectal cancer that no longer responds to standard therapies.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data on safety or effectiveness were collected. The drug may still be tested in future studies, but its benefits and risks remain unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MISMATCH REPAIR PROFICIENT COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, 45069, United States
-
University of Florida Health Science Center - Gainesville
Gainesville, Florida, 32610, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, 53718, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new blood test spot colorectal cancer return earlier?
- Experimental drug combo targets Hard-to-Treat GI cancers
- Wheat germ supplement studied for immune boost in advanced cancer
- Could a pill help the liver regrow and make more cancer surgeries possible?
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- Targeted pill aims to shrink Hard-to-Treat cancers